Exploratory secondary analysis of a phase 3 trial (n=700) in advanced urothelial carcinoma after platinum chemotherapy: avelumab maintenance plus BSC vs BSC alone had OS HR 0.77 (95% CI 0.49-1.21) in 122 with high BMI and 0.60 (0.37-0.95) in 114 with diabetes.
Secondary analysisn = 700
Aragon-Ching et al. Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus